Why the CSL (ASX:CSL) share price is seesawing over the past month

The CSL Limited (ASX: CSL) share price has been wobbling over the past few months. We take a closer look at the company, and its most recent update.
The post Why the CSL (ASX:CSL) share price is seesawing over the past month appeared first on The Motley Fool Australia. –

volatile asx share price represented by two investors on a seesaw

The CSL Limited (ASX: CSL) share price has been wobbling in recent times following the company’s ongoing plasma collection issues. Investors hit the sell button in February and March after digesting CSL’s half-year results announcement and experiencing a broader market slump thereafter.

While the global biotech’s shares have stabilised for now, the company is still facing headwinds.

At the time of writing, CSL shares are swapping hands for $271.38, up 0.16%.

What’s going on with CSL?

CSL has been in the spotlight receiving heavy media attention about its plasma stockpile, and AstraZeneca plc (NASDAQ: AZN) COVID-19 vaccine update.

First and foremost, CSL’s plasma collections have taken a hit over the past 14 months, adversely impacted by the pandemic. Fewer people are donating blood to the company’s collection centres as countries go into lockdown following new COVID-19 waves.

Plasma, derived from blood, is a key ingredient in the production of life-saving therapies. CSL’s most recent update in March advised that December 2020 plasma volumes stood at 80% of December 2019 levels.

The company has been busy targeting marketing initiatives to increase collections, along with opening new centres.

Only time will tell if the biotech leader can build back up its plasma stockpile in the short-term.

Moving on, CSL provided an update last Saturday on its COVID-19 vaccine manufacturing numbers. It said that over 1 million doses are being produced each week and is scheduled for release in mid-May. This is provided that the required quality checks are approved.

CSL noted that there is about a 4-week quality control and approval process in which each batch is stringently tested. This is undertaken by AstraZeneca, the Australian Therapeutic Goods Administration (TGA) and CSL.

To date, over 3.7 million doses of locally made AstraZeneca COVID-19 vaccines have been released. However, current COVID-19 vaccinations administered across the country stands at around 2.3 million. The remaining 1.4 million vials are either sitting in cold storage or facing transportation delays to clinics and pharmacies.

CSL share price summary

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, down 9%. The company’s shares are currently sitting just below the mid-range of $242.00 to $320.42 achieved over the year’s timeframe.

On valuation grounds, CSL is the third largest company on the ASX with a market capitalisation of roughly $123 billion.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the CSL (ASX:CSL) share price is seesawing over the past month appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!